Skip to content
HowShorted

Zentalis Pharmaceuticals, Inc. short interest in 2026

In 2026, Zentalis Pharmaceuticals, Inc.'s disclosed short interest ran from 6.69% of shares outstanding on 15 Jan 2026 to 6.68% on 15 Sep 2026, a change of -0.01 percentage points. The year's high was 8.67% on 15 Jul 2026 and its low 5.23% on 13 Feb 2026, averaging 6.91% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.50 days on 31 Mar 2026. Full history: Zentalis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Zentalis Pharmaceuticals, Inc. in 2026

2026 in figures

Start of year
6.69% (15 Jan 2026)
End of year
6.68% (15 Sep 2026)
Change
-0.01 pp
High
8.67% (15 Jul 2026)
Low
5.23% (13 Feb 2026)
Average
6.91%
Highest days to cover
8.50 (31 Mar 2026)
SEC filings marked
6

Every report in 2026

Zentalis Pharmaceuticals, Inc. short interest in 2026
SettlementShort interestDays to coverFilings since previous
15 Jan 20266.69%1.09
30 Jan 20265.57%5.36
13 Feb 20265.23%6.25
27 Feb 20265.23%6.00
13 Mar 20265.77%5.44
31 Mar 20266.01%8.5010-K filed, results (8-K)
15 Apr 20267.34%1.00
30 Apr 20267.74%3.89
15 May 20266.94%5.5410-Q filed, results (8-K)
29 May 20267.08%5.10
15 Jun 20267.02%5.64
30 Jun 20268.27%3.23
15 Jul 20268.67%6.33
31 Jul 20267.86%4.16
14 Aug 20268.33%5.3110-Q filed, results (8-K)
31 Aug 20266.96%5.13
15 Sep 20266.68%5.24

See also: Zentalis Pharmaceuticals, Inc.'s full history · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.